Abingworth
Peter was formerly Senior Vice President for Discovery Research at GlaxoSmithKline. He currently Chairs the Boards of GammaDelta Therapeutics and Adaptate Biotherapeutics. He has also held the Balfour chair in genetics at Cambridge University and research positions at the Imperial Cancer Research Fund. Peter holds doctorates from Oxford and Bristol Universities and is a Fellow of EMBO, the Academy of Medical Sciences and the Royal Society.
This person is not in the org chart
This person is not in any offices
Abingworth
1 followers
Abingworth is an international investment group dedicated to collaborating with life sciences entrepreneurs to develop their ideas into products that have a dramatic impact on health. With over $1 billion under management, Abingworth invests at all stages of development, from start-ups to publicly traded companies, and across all life sciences sectors. Supporting its portfolio companies with a team of 25 at offices in London, Menlo Park, and Boston, Abingworth has invested in 151 life science companies, completed 65 IPOs and 42 mergers and acquisitions.